XWEL · XWELL, Inc.
The latest filing states the doubt was alleviated.
“While the Company has suffered recurring losses and negative cash flows from operations, management evaluated whether substantial doubt existed about the Company’s ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued. ... Based on its current cash position and expected operating cash flows, the Company believes it has sufficient liquidity to fund its operations and meet its obligations for at least the next twelve months.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Sep 28, 2023; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XWEL
this stock
XWELL, Inc.
|
$8.42M | +113.0% | -13.8% | — | 2.6% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.5% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Sep 28, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XWEL | -4.4% | -8.4% | +188.2% | +0.0% | +113.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -4.8% | -12.9% | +174.5% | -3.9% | +99.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.